The intestinal anti-inflammatory activity of UR-12746S on reactivated experimental colitis is mediated through downregulation of cytokine production

Inflammatory Bowel Diseases

Volumn 9, Issue 6, 2003, Pages 363-371

  Gálvez, Julio ^a   Garrido, Margarita ^a   Rodríguez Cabezas, Maria Elena ^a   Ramis, Isabel ^b   Sánchez de Medina, Fermín ^a   Merlos, Manuel ^b   Zarzuelo, Antonio ^a  

^a UNIVERSITY OF GRANADA   (Spain)

^b Grupo Uriach   (Spain)

Author keywords

Il 1 ; IL 8; Rat experimental colitis; TNF ; UR 12746S (dersalazine sodium)

Indexed keywords

1 [3 (4 AMINOPHENYL) 1 OXO 3 PHENYL 2 PROPENYL] 4 [(2 METHYL 1H IMIDAZO[4,5 C]PYRIDIN 1 YL)METHYL]PIPERIDINE; ALCOHOL; ANTIINFLAMMATORY AGENT; BIOCHEMICAL MARKER; CYTOKINE; DERSALAZINE SODIUM; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; MESALAZINE; MYELOPEROXIDASE; PHORBOL 13 ACETATE 12 MYRISTATE; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UR 12715; UR 12746S;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASSAY; CELL STIMULATION; CELL STRAIN HT29; CELL STRAIN U937; COLITIS; COLON INJURY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DOWN REGULATION; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; INTESTINE FLORA; NONHUMAN; PRIORITY JOURNAL; RAT; RELAPSE;

AMINOSALICYLIC ACIDS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AZA COMPOUNDS; CELL LINE; COLITIS; COLON; CYTOKINES; DOWN-REGULATION; FEMALE; INFLAMMATION MEDIATORS; INTERLEUKIN-1; INTERLEUKIN-8; MESALAMINE; NEUTROPHIL INFILTRATION; PEROXIDASE; PLATELET ACTIVATING FACTOR; RATS; RATS, WISTAR; RECURRENCE; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0344466539     PISSN: 10780998     EISSN: None     Source Type: Journal    
DOI: 10.1097/00054725-200311000-00004     Document Type: Article

References (38)

1. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology. 1998;115:182-205.
2. Katz JA, Itoh J, Fiocchi C. Pathogenesis of inflammatory bowel disease. Curr Opin Gastroenterol. 1999;15:291-297.
3. Podolsky DK, Fiocchi C. Cytokines, chemokines, growth factors, eicosanoids and other bioactive molecules in inflammatory bowel disease. In: Kirsner JB, ed. Inflammatory Bowel Disease. 5th Ed. Philadelphia: WB Saunders, 2000:191-207.
4. Kho YH, Pool MO, Jansman FG, et al. Pharmacotherapeutic options in inflammatory bowel disease: an update. Pharm World Sci. 2001;23:17-21.
5. Galvez J, Garrido M, Merlos M, et al. Intestinal anti-inflammatory activity of UR-12746, a novel 5-ASA conjugate, on acute and chronic experimental colitis in the rat. Br J Pharmacol. 2000;130: 1949-1959.
6. Travis SPL, Jewell DP. Salicylates for ulcerative colitis-their mode of action. Pharmacol Ther. 1994;63:135-161.
7. Makins RJ, Cowan RE. 5-amino-salicylate in the management of inflammatory bowel disease. Colorectal Dis. 2001;3:218-222.
8. Wallace JL. Release of platelet-activating factor (PAF) and accelerated healing induced by a PAF antagonist in an animal model of chronic colitis. Can J Physiol Pharmacol. 1988;66:422-425.
9. Meenan J, Grool TA, Hommes DW, et al. Lexipafant (BB-882), a platelet activating antagonist, ameliorates mucosal inflammation in an animal model of colitis. Eur J Gastroenterol Hepatol. 1996;8: 569-583.
10. Morris GP, Beck PL, Herridege W, et al. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology. 1989;96:795-803.
11. Bell CJ, Gall DG, Wallace JL. Disruption of colonic electrolyte transport in experimental colitis. Am J Physiol. 1995;268: G622-G630.
12. Krawisz JE, Sharon P, Stenson WF. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology. 1984;87:1344-1350.
13. Balsa D, Merlos M, Giral M, et al. Effects of a new antagonist of platelet-activating factor, UR-12670, on several endotoxic shock markers in rats. Drugs Exp Clin Res. 1997;23:191-199.
14. Cruz T, Galvez J, Ocete MA, et al. Oral administration of rutoside can ameliorate inflammatory bowel disease in rats. Life Sci. 1998; 62:687-695.
15. Yamada T, Marshall S, Specian RD, et al. A comparative study of two models of experimental colitis in rats. Gastroenterology. 1992; 102:1524-1534.
16. Appleyard CB, Wallace JL. Reactivation of hapten-induced colitis and its prevention by anti-inflammatory drugs. Am J Physiol. 1995; 269:G119-G125.
17. Wallace JL, McKnight W, Asfaha S, et al. Reduction of acute and reactivated colitis in rats by an inhibitor of neutrophil activation. Am J Physiol. 1998;274:G802-G808.
18. Bossone C, Hosseini JM, Piñeiro-Carrero V, et al. Alteration in spontaneous contractions in vitro after repeated inflammation of rat distal colon. Am J Physiol. 2001;280:G949-G957.
19. Veljaca M, Lesch CA, Pllana R, et al. BPC-15 reduces trinitrobenzene sulfonic-induced colonic damage in rats. J Pharmacol Exp Ther. 1995;272:417-422.
20. Rachmilewitz D, Simon PL, Schwartz LW, et al. Inflammatory mediators of experimental colitis in rats. Gastroenterology. 1989; 97:357-367.
21. Beck PL, Wallace JL. Cytokines in inflammatory bowel disease. Med Inflamm. 1997;6:95-103.
22. Sanchez de Medina F, Galvez J, Romero JA, et al. Effect of quercitrin on acute and chronic experimental colitis in the rat. J Pharmacol Exp Ther. 1996;278:771-779.
23. Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology. 1999; 117:761-769.
24. Present DH. Review article: the efficacy of infliximab in Crohn's disease-healing of fistulae. Aliment Pharmacol Ther. 1999; 13:23-28.
25. Chey WY. Infliximab for patients with refractory ulcerative colitis. Inflamm Bowel Dis. 2001;7:S30-S33.
26. Yoshimura T, Matsushima K, Tanaka S, et al. Purification of a human monocyte-derived neutrophil chemotactic factor that has a peptide sequence similarity to other host defense cytokines. Proc Natl Acad Asc USA. 1987;84:9233-9237.
27. van Deventer SJ. Review article: Chemokine production by intestinal epithelial cells: a therapeutic target in inflammatory bowel disease? Aliment Pharmacol Ther. 1997;11:116-120.
28. Ferraris L, Karmeli F, Eliakim R, et al. Intestinal epithelial cells contribute to the enhanced generation of platelet-activating factor in ulcerative colitis. Gut. 1993;34:665-668.
29. 2 and tumor necrosis-alpha induce differential binding to the redoxresponsive transcription factors AP-1 and NF-κB to the interleukin-8 promoter in endothelial and epithelial cells. J Biol Chem. 1998;273:32670-32678.
30. Pei Y, Barber LA, Murphy RC, et al. Activation of the epidermal platelet-activating factor results in cytokine and cyclooxygenase-2 biosynthesis. J Immunol. 1998;161:1954-1961.
31. 2 before and after induction of colitis with trinitrobenzenesulfonic acid in rats decreases inflammation. Gastroenterology. 1989;96:1290-1300.
32. Ahnfelt-Ronne I, Nielsen OH, Christensen A, et al. Clinical evidence supporting the radical scavenger mechanism of 5-aminosalicylic acid. Gastroenterology. 1990;98:1162-1169.
33. Gutierrez-Ruiz MC, Quiroz SC, Souza V, et al. Cytokines, growth factors, and oxidative stress in HepG2 cells treated with ethanol, acetaldehyde, and LPS. Toxicology. 1999;134:197-207.
34. Han SJ, Ko HM, Choi JH, et al. Molecular mechanisms for lipopolysaccharide-induced biphasic activation of nuclear factor-κB (NF-κB). J Biol Chem. 2002;47:44715-44721.
35. Poubelle PE, Gingras D, Demers C, et al. Platelet-activating factor (PAF-acether) enhances the concomitant production of tumor necrosis factor-alpha and interluekin-1 by subsets of human monocytes. Immunology. 1991;72:181-187.
36. Bussolino F, Camussi G, Baglioni C. Synthesis and release of platelet-activating factor by human vascular endothelial cells treated with tumor necrosis factor or interleukin 1 alpha. J Biol Chem. 1988;263:11856-11861
37. Tsuyuki K, Ichinowatari G, Tanimoto A. Possible participation of intracellular platelet-activating factor in NF-κB activation in rat peritoneal macrophages. Biochim Biophys Acta. 2002;1583:26-34.
38. Müller S, Nigam S. Enhancement by staurosporine of platelet-activating factor formation in N-formyl peptide-challenged human neutrophils is mediated by intracellular platelet-activating factor binding sites. Biochem Biophys Res Commun. 1992;189:771-776.